UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

Position in CLLS — Cellectis S.A.

CIK 861177 NEW YORK, NY

Back to CLLS Full portfolio

Position in CLLS

as of Mar 31, 2026 · filed May 13, 2026 Compact

Position Value

$10,076,224

-$5,308,296 QoQ

Shares Held

3,178,620

0.0% QoQ

Ownership

3.16%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Jun 2024

7 quarters on record

Voting authority Sole 41.04255934965488.ToString("F0")% Shared 0.ToString("F0")% None 58.95744065034512.ToString("F0")%

Common Shares in CLLS Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Mar 31, 2026

UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC holds $4,287,037,771 across 211 Biotechnology names. CLLS ranks #40 (0.2% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	3,057,396	$1,365,249,602
2	REGN	Regeneron Pharmaceuticals, Inc.	723,621	$559,098,523
3	ALNY	Alnylam Pharmaceuticals, Inc.	677,519	$224,170,706
4	INSM	INSMED Inc	1,215,025	$198,680,883
5	RPRX	Royalty Pharma plc	3,095,766	$148,503,890
6	INCY	Incyte Corp	1,540,913	$145,030,725
7	IONS	Ionis Pharmaceuticals Inc	1,475,632	$110,805,201
8	DNLI	Denali Therapeutics Inc.	4,432,314	$85,100,425

All Filings in CLLS

Export CSV

7 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$10,076,224	3,178,620	0.0%	Shares	Sole	2026-05-13
2025-12-31	$15,384,520	3,178,620	0.0%	Shares	Sole	2026-02-13
2025-06-30	$4,847,395	3,178,620	-32.7%	Shares	Other	2025-08-14
2025-03-31	$5,856,102	4,722,664	+228.4%	Shares	Other	2025-05-19
2024-12-31	$2,588,859	1,438,255	0.0%	Shares	Sole	2025-02-14
2024-09-30	$3,049,100	1,438,255	0.0%	Shares	Defined	2024-11-14
2024-06-30	$2,689,536	1,438,255	—	Shares	Defined	2024-08-14
No filing history on record for this holder in this stock.